(0 items)
Small Medium Large | Print-Friendly Version of this Page  | Email this Page to a Friend
Skip Navigation Links
Press Releases
Hot Topics
Statements
Comments
Correspondence
White Papers
Contact Public Relations
AABB > Press Room > Press Releases

For Immediate Release
October 14, 2009 
Jennifer Garfinkel
+1.301.215.6526
publicrelations@aabb.org
Contact:
 

 Transfusion Medicine and Cellular Therapies Professionals to Gather in New Orleans to Discuss Latest Developments at AABB Annual Meeting and TXPO 

 
WHEN: Saturday, October 24 - Tuesday, October 27, 2009
WHERE: Ernest N. Morial Convention Center
900 Convention Center Blvd.
New Orleans, La., USA

HIGHLIGHTS:  Educational programs and discussions will include:

 

What's New in Transfusion-Transmitted Infections? (Session 9101-S)

The speakers in this session will discuss the proposed use of selected testing strategies for emerging infections; a new TRANSFUSION supplement on emerging infection agents posing risks to the blood supply; and the mechanisms underlying the emergence of arthropod-borne viruses in the U.S. While routine testing for infectious agents such as HIV and hepatitis have been effective in preventing the transmission of these diseases through blood transfusions, some of the new infectious risks of blood transfusion will need to be addressed differently. Understanding the epidemiology of these emerging infections as well as evaluating the efficacy of selective donor testing approaches in preventing the transmission of TTD is critical to ensuring the safety of the blood supply.

 

TRALI Risk Reduction: What Have We Learned? (Session 9327-TC)
There has been increasing recognition of transfusion-related acute lung injury (TRALI) as a serious complication of transfusion. Various approaches to mitigating TRALI risk for high plasma volume blood products have been discussed and, in some cases, implemented. While no single action can be taken to reduce the risk of TRALI, an array of interventions can be implemented at different stages in the blood collection and selection process.  In the case of transfusable plasma products, a common approach has been the use of male-predominant plasma. In the case of apheresis platelets, there has been little consensus on what approach should be used with much controversy over the need for leukocyte antibody testing of some or all apheresis donors. The pros and cons of various approaches will be discussed and new data on current practices from a recently completed survey of AABB members will be presented.

 

Additional Hot Topics:

·               Managing the Transfusion Service During the Economic Crisis (Session 9121-TC)

·               Novel Therapeutic Uses of Umbilical Cord Blood (Session 9220-TC-CT)

Ø  Panel includes Michael Haller, MD, pediatric endocrinologist who pioneered a study to determine the effect of using cord blood in patients with type 1 diabetes.

·               Randomized Clinical Trials in Transfusion (Session 9103-S)

Ø  Two eminent clinical investigators will present the results of recent and important randomized clinical trials that compare outcomes of surgical patients transfused at different hemoglobin triggers.

 

To receive a complimentary press registration, please call +1.301.215.6526, or email publicrelations@aabb.org.  For more information about AABB’s Annual Meeting, visit: www.aabb.org under “Meetings and Events > Annual Meeting and TXPO."

###

Home  |  Site Map  | AABB © 2014. All rights reserved. |  Privacy Statement  |  Terms of Use